Successful Treatment with Nedaplatin in Patients with Ovarian Cancer that Recurred after Platinum-containing Chemotherapy: Report of Two Cases

Japanese Journal of Clinical Oncology

Volumn 28, Issue 5, 1998, Pages 343-346

  Itoh, Kuniaki ^a   Yamashita, Tomoyuki ^a   Wakita, Hisashi ^a   Watanabe, Yuko ^a   Kodama, Keiji ^a   Fujii, Hirofumi ^a   Minami, Hironobu ^a   Ohtsu, Tomoko ^a   Igarashi, Tadahiko ^a   Sasaki, Yasutsuna ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

cis diammineglycolatoplatinum; Ovary; Palliative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; NEDAPLATIN; PLATINUM COMPLEX;

ADENOCARCINOMA; ARTICLE; CASE REPORT; DRUG ADMINISTRATION; FEMALE; HUMAN; MIDDLE AGED; OVARY TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA, PAPILLARY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 0032059824     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.5.343     Document Type: Article

References (24)

1. Neijt JP. Treatment of advanced ovarian cancer: 10 years experience. Ann Oncol 1992;3:17-27.
2. Christian MC, Trimble EL Salvage chemotherapy for ovarian carcinoma. Gynecol Oncol 1994;55:S143-50
3. Ozols RF. Treatment of recurrent ovarian cancer Increasing options - recurrent' results. J Clin Oncol 1997;15:2177-80.
4. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, et al. Phase II study of (glycolato-O.O) diammineplatinum(II). a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990;26:393-6.
5. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, et al. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. Can To Kagaku Ryoho 1992;19:483-8 (in Japanese).
6. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K. A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho 1992;19:871-7 (in Japanese).
7. Akaza H, Togashi M, Nishio Y, Mild T, Kotake T, Matsumura Y, et al. Phase II study of cis-diamrnine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 1992;31:187-92
8. Kato T, Nishimura H, Yakushiji M, Noda K, Terashima Y, Takeuchi S, et al Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Can To Kagaku Ryoho 1992;19:695-701 (in Japanese).
9. Ariyoshi Y, Ota K, Wakui A, Majima H, Niitani H, Ogawa M, et al. Phase I study of (glycolato-O,O) diammine platinum(II) (254-S). Proc ASCO 1988;7:59.
10. Dunton CJ. New options for the treatment of advanced ovarian cancer. Semin Omol 1997;24:S5-2-11.
11. McGuire WP, Hoskins WJ, Brady MK, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage in and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
12. Huinink WTB, Carmichael J, Armstrong D, Gordon A, Malfetano J. Efficacy and safety of topotecan in the treatment of advanced ovarian cancer. Semin Oncol 1997;24:S5-19-25.
13. Lund B, Neijt JP. Gemcitabine in cisplatin-resistant ovarian cancer. Semia Oncol 1996;23:72-6
14. Tate-Thigpen J, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993;71:1559-64.
15. Bolis G, Scarfone G, Luchini L, Ferraris C, Zanaboni F, Presti M, et al. Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatm-based regimen. Eur J Cancer 1994;30A: 1764-8.
16. Markman M, Reichman B, Hakes T, Lones W, Lewis JL Jr, Rubin S, et al. Response to second-line cisplatin-based intraperitoneal therapy in ovarian cancer Influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9:1801-5.
17. Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Lones W, et al. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol 1989;7:1327-32.
18. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous Cyclophosphamide for stage 111 ovarian cancer. N Engl J Med 1996;335:1950-5.
19. Dedrick RL, Flessner MF. Pharmacokinetic problem in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst 1997;89:480-7.
20. Takeuchi S, Takamizawa H, Takeda Y, Ohkawa T, Tamaya T, Noda K, et al. An early phase II study of CPT-11 for gynecological cancers. Can To Kagaku Ryoho 1991;18-579-84(in Japanese).
21. Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer J Clin Oncol 1994;12:2066-70.
22. Alberts DS, Fanta PT, Running KL, Adair LP, Garcia JDJ, Liu-Stevens R, et al. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol 1997;39:493-7
23. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, et al Pharmacokinetics of (glycolato-O,O)-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 1989;23:243-6.
24. Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Ohmori T, et al. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay. Cancer Chemother Pharmacol 1991;27:263-70.